选择性前列环素受体激动剂selexipag:一种治疗肺动脉高压的口服新药

Selexipag: a new, oral and selective prostacyclin receptor agonist for pulmonary arterial hypertension

肺动脉高压(PAH)是一种以肺血管阻力增加导致右测心力衰竭甚至死亡的进行性疾病。目前,PAH靶向治疗药物主要包括磷酸二酯酶5抑制剂、内皮素受体拮抗剂、前列腺素类似物等。selexipag是一种新型的口服前列环素受体激动剂,可松弛血管壁平滑肌、扩张血管、降低肺动脉压力。该药具有高选择性、作用时间长等特点,可作为PAH的一线治疗药物。在一系列临床研究中均显示出良好的应用前景,具有较好的安全性和耐受性。

Pulmonary arterial hypertension （PAH） is a progressive disease characterized by elevation of pulmonary vascular resistance that results in right heart failure and death. The targeted therapy for PAH patients includes phosphodiesterase antagonist- 5 inhibitors, endothelin receptor antagonists and prostacyclin analogs. Selexipag is a new orally available prostacyclin receptor agonist which can relax vascular smooth muscle, dilate vessels and reduce pulmonary arterial pressure. Selexipag can be used for the treatment of PAH as a first-line agent characterized by high selectivity and long time action. It showed a good prospect in a series of clinical trials with good tolerability and safety.